Boehringer Ingelheim has announced the launch of Mirapexin (pramipexole) in a new once-daily form to help patients deal with the debilitating symptoms of Parkinson’s disease.

Mirapexin is the world’s most widely prescribed dopamine agonist for the treatment of Parkinson’s disease, and doctors believe the new formulation will improve patients sticking to treatment regimes as they only have to take it once.

Patients taking Mirapexin in the three-times-a-day form should be able to switch to the once-daily prolonged-release formulation overnight and studies support this with almost 85% of patients successfully switched to the once-daily overnight.

In clinical trials, once-daily Mirapexin prolonged release was as effective as the three-times-a-day formulation at the same daily dose.